Search

Your search keyword '"Kuball, Jürgen"' showing total 360 results

Search Constraints

Start Over You searched for: Author "Kuball, Jürgen" Remove constraint Author: "Kuball, Jürgen" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
360 results on '"Kuball, Jürgen"'

Search Results

1. BEHAV3D: a 3D live imaging platform for comprehensive analysis of engineered T cell behavior and tumor response

2. CRISPR screens decode cancer cell pathways that trigger γδ T cell detection.

5. Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

6. Dual targeting of cancer metabolome and stress antigens affects transcriptomic heterogeneity and efficacy of engineered T cells

7. Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT

9. Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

11. Uncovering the mode of action of engineered T cells in patient cancer organoids

12. GoCART

14. Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT

15. In vitro T cell responses to PD-1 blockade are reduced by IFN-α but do not predict therapy response in melanoma patients.

18. Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

19. Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT

20. Efficacy and safety of daratumumab in pure red cell aplasia after allogeneic transplantation: Dutch real-world data

22. Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT

23. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

26. Reactivation of Multidrug-Resistant HSV-1 in a Post–Allogenic Hematopoietic Stem Cell Transplant Patient: Dynamic Detection of the Rare A605V Mutation by Next-Generation Sequencing.

29. Lymphodepletion – an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle

30. Dual targeting of cancer metabolome and stress antigens affects transcriptomic heterogeneity and efficacy of engineered T cells

31. Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study

32. Basics of Advanced Therapy Medicinal Product Development in Academic Pharma and The Role of a GMP Simulation Unit

33. Efficacy of MSC for steroid-refractory acute GVHD associates with MSC donor age and a defined molecular profile

34. Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia

35. Compatibility at amino acid position 98 of MICB reduces the incidence of graft-versus-host disease in conjunction with the CMV status

36. Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT

37. Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

39. Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia: A Study on Behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

40. Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study.

44. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML

45. Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition.

48. Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD

49. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

50. Immune monitoring in allogeneic hematopoietic stem cell transplant recipients: a survey from the EBMT-CTIWP

Catalog

Books, media, physical & digital resources